Dowell, S. F. & Ho, M. S. Seasonality of infectious diseases and severe acute respiratory syndromewhat we dont know can hurt us. Lancet Infect. Dis. 4, 704708 (2004).
Article Google Scholar
Bygbjerg, I. C. Double burden of noncommunicable and infectious diseases in developing countries. Science 337, 14991501 (2012).
Article Google Scholar
Baker, R. E. et al. Infectious disease in an era of global change. Nat. Rev. Microbiol. 20, 193205 (2022).
Article Google Scholar
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533534 (2020).
Article Google Scholar
Mosier, D. A. Bacterial pneumonia. Vet. Clin. North. Am. Food Anim. Pract. 13, 483493 (1997).
Article Google Scholar
Bradley, B. T. & Bryan, A. Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. Semin. Diagn. Pathol. 36, 152159 (2019).
Article Google Scholar
Shao, X. et al. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175, 32443251 (2005).
Article Google Scholar
Zhou, P. & Shi, Z.-L. SARS-CoV-2 spillover events. Science 371, 120122 (2021).
Article Google Scholar
Abraham, E. et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit. Care Med. 28, 232235 (2000).
Article Google Scholar
DiSilvio, B. et al. Complications and outcomes of acute respiratory distress syndrome. Crit. Care Med. 42, 349361 (2019).
Google Scholar
Li, K. et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 213, 712722 (2016).
Article Google Scholar
Singh, A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 16, 1624 (2021).
Article Google Scholar
Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553559 (2021).
Article Google Scholar
Su, Z. et al. Bioresponsive nano-antibacterials for H2S-sensitized hyperthermia and immunomodulation against refractory implant-related infections. Sci. Adv. 8, eabn1701 (2022).
Article Google Scholar
Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug. Discov. 20, 817838 (2021).
Article Google Scholar
Wareing, M. D. & Tannock, G. A. Live attenuated vaccines against influenza; an historical review. Vaccine 19, 33203330 (2001).
Article Google Scholar
Skountzou, I. et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28, 41034112 (2010).
Article Google Scholar
Ellebedy, A. H. et al. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) virus vaccination in ferrets. Clin. Vaccine Immunol. 17, 19982006 (2010).
Article Google Scholar
Ninomiya, A. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20, 31233129 (2002).
Article Google Scholar
Roy, S. et al. Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. Vaccine 37, 12661276 (2019).
Article Google Scholar
Mielcarek, N., Alonso, S. & Locht, C. Nasal vaccination using live bacterial vectors. Adv. Drug. Deliv. Rev. 51, 5569 (2001).
Article Google Scholar
Wu, Y. et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci. Transl. Med. 13, eabg1143 (2021).
Article Google Scholar
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
Article Google Scholar
Narasimhan, M. et al. Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines 9, 708 (2021).
Article Google Scholar
Berkhout, B., Verhoef, K., van Wamel, J. L. B. & Back, N. K. T. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J. Virol. 73, 11381145 (1999).
Article Google Scholar
Cevik, M. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 184, 50775081 (2021).
Article Google Scholar
KhalajHedayati, A., Chua, C. L. L., Smooker, P. & Lee, K. W. Nanoparticles in influenza subunit vaccine development: immunogenicity enhancement. Influenza Other Resp. Vir. 14, 92101 (2020).
Article Google Scholar
Kim, C. G., Kye, Y.-C. & Yun, C.-H. The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8+ T cell responses. Pharmaceutics 11, 612 (2019).
Article Google Scholar
Silva, A. L., Soema, P. C., Sltter, B., Ossendorp, F. & Jiskoot, W. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum. Vaccines Immunother. 12, 10561069 (2016).
Article Google Scholar
Huang, J. et al. Nasal nanovaccines for SARS-CoV-2 to address COVID-19. Vaccines 10, 405 (2022).
Article Google Scholar
Hussain, A. et al. mRNA vaccines for COVID-19 and diverse diseases. J. Control. Rel. 345, 314333 (2022).
Article Google Scholar
Meng, Q. et al. Capturing cytokines with advanced materials: a potential strategy to tackle COVID19 cytokine storm. Adv. Mater. 33, 2100012 (2021).
Article Google Scholar
Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E. & Ferguson, T. A. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15, 496497 (2009).
Article Google Scholar
van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 3950 (2022).
Article Google Scholar
Wykes, M. N. & Lewin, S. R. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91104 (2018).
Article Google Scholar
Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630645 (2020).
Article Google Scholar
Jiang, S., Zhang, X., Yang, Y., Hotez, P. J. & Du, L. Neutralizing antibodies for the treatment of COVID-19. Nat. Biomed. Eng. 4, 11341139 (2020).
Article Google Scholar
Nasiruddin, M., Neyaz, Md. K. & Das, S. Nanotechnology-based approach in tuberculosis treatment. Tuberc. Res. Treat. 2017, 112 (2017).
Google Scholar
Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 16371645 (2021).
Article Google Scholar
The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 14911502 (2021).
Article Google Scholar
Kozlov, M. Omicron overpowers key COVID antibody treatments in early tests. Nature https://doi.org/10.1038/d41586-021-03829-0 (2021).
Roback, J. D. & Guarner, J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 323, 15611562 (2020).
Article Google Scholar
Nguyen, P. T. N., Nho Van Le, Nguyen Dinh, H. M., Nguyen, B. Q. P. & Nguyen, T. V. A. Lung penetration and pneumococcal target binding of antibiotics in lower respiratory tract infection. Curr. Med. Res. Opin. 38, 20852095 (2022).
Article Google Scholar
Qiao, Q. et al. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design. Acta Pharm. Sin. B 11, 30603091 (2021).
Article Google Scholar
Duan, Y., Wang, S., Zhang, Q., Gao, W. & Zhang, L. Nanoparticle approaches against SARS-CoV-2 infection. Curr. Opin. Solid. State Mater. Sci. 25, 100964 (2021).
Article Google Scholar
Doroudian, M., MacLoughlin, R., Poynton, F., Prina-Mello, A. & Donnelly, S. C. Nanotechnology based therapeutics for lung disease. Thorax 74, 965976 (2019).
Article Google Scholar
Yang, H. et al. Amino acid-dependent attenuation of Toll-like receptor signalling by peptide-gold nanoparticle hybrids. ACS Nano 9, 67746784 (2015).
Article Google Scholar
Gao, Y., Dai, W., Ouyang, Z., Shen, M. & Shi, X. Dendrimer-mediated intracellular delivery of fibronectin guides macrophage polarization to alleviate acute lung injury. Biomacromolecules 24, 886895 (2023).
Article Google Scholar
Liu, F.-C. et al. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J. Nanobiotechnol. 16, 35 (2018).
Article Google Scholar
Kou, M. et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis. 13, 580 (2022).
Article Google Scholar
Liu, W. et al. Recent advances of cell membrane-coated nanomaterials for biomedical applications. Adv. Funct. Mater. 30, 2003559 (2020).
Read more:
Immunoregulatory nanomedicine for respiratory infections - Nature.com
Recommendation and review posted by G. Smith
